Literature DB >> 21471841

In vitro characterization of the angiogenic phenotype and genotype of the endothelia derived from sporadic cerebral cavernous malformations.

Yuan Zhu1, Qun Wu, Moritz Fass, Jin-Fang Xu, Chao You, Oliver Müller, I Erol Sandalcioglu, Jian-Min Zhang, Ulrich Sure.   

Abstract

BACKGROUND: Cerebral cavernous malformation (CCM) is mainly a disorder of endothelial cells. Although the endothelial function of CCM genes has been characterized in familial CCMs, little attention has been paid to the pathological alterations of the endothelium in sporadic CCMs.
OBJECTIVE: We assumed that the endothelia derived from sporadic CCMs present genotypic and/or phenotypic alterations and exhibit unique responses to the pathogenic stimuli.
METHODS: Endothelial cells were prepared from fresh operative specimens of sporadic CCMs with a single lesion (CCM-ECs, n = 20). The expression of VEGF and its receptors and CCM1-3 genes were detected by real-time reverse transcriptase polymerase chain reaction (RT-PCR). Endothelial cell proliferation, migration, sprouting, and tube formation were compared between CCM-ECs and control endothelial cells after different angiogenic stimuli and after silencing CCM1.
RESULTS: RT-PCR revealed a highly activated VEGF system in CCM-ECs without significant alteration in CCM1-3 gene expression. Accordingly, CCM-ECs exhibited great growth potential under normal culture conditions and a significantly high proliferation activity in response to various angiogenic stimuli including hypoxia, fetal calf serum, and vascular endothelial growth factor treatment. A considerably higher mobility, spontaneous sprouting and extensive tube-branching were exclusively detected in CCM-ECs. In comparison with control endothelia, CCM-EC resisted apoptotic stimuli and showed distinct responses to activating angiogenesis after silencing CCM1.
CONCLUSION: Distinct genotypic and phenotypic features occur in CCM-EC independently from the deficiency in CCM1-3 gene expression. The distinct responses of CCM-EC to different pathogenic stimuli suggest that CCM-EC is a valuable in vitro model for further study of CCMs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471841     DOI: 10.1227/NEU.0b013e318219569f

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  11 in total

1.  A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.

Authors:  Lisa McKerracher; Robert Shenkar; Matthew Abbinanti; Ying Cao; Amy Peiper; James K Liao; Rhonda Lightle; Thomas Moore; Nicholas Hobson; Carol Gallione; Joerg Ruschel; Janne Koskimäki; Romuald Girard; Kenneth Rosen; Douglas A Marchuk; Issam A Awad
Journal:  Transl Stroke Res       Date:  2019-08-24       Impact factor: 6.829

Review 2.  PTEN/PI3K/Akt/VEGF signaling and the cross talk to KRIT1, CCM2, and PDCD10 proteins in cerebral cavernous malformations.

Authors:  Souvik Kar; Amir Samii; Helmut Bertalanffy
Journal:  Neurosurg Rev       Date:  2014-11-19       Impact factor: 3.042

3.  Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.

Authors:  Romuald Girard; Hussein A Zeineddine; Maged D Fam; Anoop Mayampurath; Ying Cao; Changbin Shi; Robert Shenkar; Sean P Polster; Michael Jesselson; Ryan Duggan; Abdul-Ghani Mikati; Gregory Christoforidis; Jorge Andrade; Kevin J Whitehead; Dean Y Li; Issam A Awad
Journal:  Transl Stroke Res       Date:  2017-08-17       Impact factor: 6.829

4.  Neurovascular Manifestations of Hereditary Hemorrhagic Telangiectasia: A Consecutive Series of 376 Patients during 15 Years.

Authors:  W Brinjikji; V N Iyer; V Yamaki; G Lanzino; H J Cloft; K R Thielen; K L Swanson; C P Wood
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-24       Impact factor: 3.825

5.  Adaptor protein cerebral cavernous malformation 3 (CCM3) mediates phosphorylation of the cytoskeletal proteins ezrin/radixin/moesin by mammalian Ste20-4 to protect cells from oxidative stress.

Authors:  Miguel Fidalgo; Ana Guerrero; María Fraile; Cristina Iglesias; Celia M Pombo; Juan Zalvide
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

Review 6.  Cerebral cavernous malformation proteins at a glance.

Authors:  Kyle M Draheim; Oriana S Fisher; Titus J Boggon; David A Calderwood
Journal:  J Cell Sci       Date:  2014-01-30       Impact factor: 5.285

Review 7.  Vis-à-vis: a focus on genetic features of cerebral cavernous malformations and brain arteriovenous malformations pathogenesis.

Authors:  Concetta Scimone; Luigi Donato; Silvia Marino; Concetta Alafaci; Rosalia D'Angelo; Antonina Sidoti
Journal:  Neurol Sci       Date:  2018-12-06       Impact factor: 3.307

8.  Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.

Authors:  Romuald Girard; Hussein A Zeineddine; Janne Koskimäki; Maged D Fam; Ying Cao; Changbin Shi; Thomas Moore; Rhonda Lightle; Agnieszka Stadnik; Kiranj Chaudagar; Sean Polster; Robert Shenkar; Ryan Duggan; David Leclerc; Kevin J Whitehead; Dean Y Li; Issam A Awad
Journal:  Circ Res       Date:  2018-05-02       Impact factor: 17.367

9.  PHACE syndrome is associated with intracranial cavernous malformations.

Authors:  Kimberly A Foster; William J Ares; Zachary J Tempel; Andrew A McCormick; Ashok Panigrahy; Lorelei J Grunwaldt; Stephanie Greene
Journal:  Childs Nerv Syst       Date:  2016-04-28       Impact factor: 1.475

10.  Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations.

Authors:  Chao You; Ibrahim Erol Sandalcioglu; Philipp Dammann; Ute Felbor; Ulrich Sure; Yuan Zhu
Journal:  J Cell Mol Med       Date:  2013-02-07       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.